Ten years ago, the inhibition of Rho kinase by intracavernosal injection of Y-27632 was found to induce an erectile response. This effect did not require activation of nitric oxide-mediated signaling, introducing a novel target pathway for the treatment of erectile dysfunction (ED), with potential added benefit in cases where nitric oxide bioavailability is attenuated (and thus phosphodiesterase type 5 (PDE5) inhibitors are less efficacious). Rho-kinase antagonists are currently being developed and tested for a wide range of potential uses. The inhibition of this calcium-sensitizing pathway results in blood vessel relaxation. It is also possible that blockade of additional smooth muscle contractile signaling mechanisms may have the same effect. In this review, we conducted an extensive search of pertinent literature using PUBMED. We have outlined the various pathways involved in the maintenance of penile smooth muscle tone and discussed the current potential benefit for the pharmacological inhibition of these targets for the treatment of ED.
Introduction
Erectile dysfunction (ED) affects 30 million men in the United States 1 and is associated with co-morbidities ranging from prostatectomy to diabetes and increased age. Penile erection is a dynamic process requiring dilation of feeder arterioles and cavernosal sinusoids allowing for increased inflow of blood. It is important to remember, however, that the vast majority of the time, these arterioles and sinusoids are maintained in the collapsed/contracted state, severely restricting penile blood flow. 2 The maintenance of penile flaccidity through vasomotor tone is an active process involving complex signaling mechanisms. Heightened smooth muscle contraction is present in some models of ED, 3, 4 and various studies have suggested that pharmacological inhibition of smooth muscle contraction, as opposed to active induction of dilation (such as through nitric oxide (NO)-mediated pathways), may be a beneficial strategy for the treatment of ED. [5] [6] [7] In this review, we will outline the major smooth muscle signaling pathways involved in penile vasoconstriction and discuss the potential for inhibition of these pathways as a treatment option for organic ED. A focus will be on the promise and limitations of pharmacological therapy based on current progress in the development of RhoA/ Rho-kinase (ROCK) antagonists.
Contractile signaling
The vast majority of time, the penis is maintained in the flaccid state through active contraction of penile arterioles. The release of norepinephrine (NE) from sympathetic nerve terminals activates arteriolar and cavernosal a-adrenergic receptors. 2, 8, 9 Subsequent increases in intracellular Ca 2 þ concentration ([Ca 2 þ ] i ) result in the activation of myosin light-chain kinase (MLCK) and phosphorylation of myosin light chain (MLC), enabling actin-myosin cross-bridge cycling. In addition to the Ca 2 þ -dependent contractile mechanism, Ca 2 þ -sensitizing pathways, such as ROCK-and protein kinase C (PKC)-mediated signaling, can promote contraction through the inhibition of MLC phosphatase or the direct stimulation of MLC phosphorylation. 10, 11 Both Ca 2 þ -dependent and Ca 2 þ -sensitizing signaling can be activated by NE or other agonists, including endothelin-1 (ET-1), serotonin (5-HT) and angiotensin-II (Ang-II). 4, 10, [12] [13] [14] [15] Upstream signaling: NE, ET-1, 5-HT and Ang-II NE. It is generally accepted that penile detumescence and flaccidity are achieved mainly by constant sympathetic input. 2 Both cavernous smooth muscle (CSM) and the smooth muscle of the penile arteries and veins are rich in sympathetic innervation. Upon activation, the sympathetic nerve terminals release NE, which binds to and stimulates a-adrenoceptors on the smooth muscle membrane. 16, 17 The activation of a-adrenoceptors triggers a series of intracellular signaling pathways involving both Ca 2 þ -dependent 12, 13 and Ca 2 þ -sensitizing mechanisms, 10, 11 to induce contraction.
ET-1. ET-1, a member of the ET family of peptides, is among the strongest vasoconstrictors known. ET-1 is produced primarily in the endothelium and plays an important role in vascular homeostasis. 18 In the corpus cavernosum (CC), ET-1 elicits slow-developing but strong, long-lasting contractions. 19 Smooth muscle cells including CSM cells express two subtypes of ET-1 receptors: ET A and ET B . 19 The binding of ET-1 to ET A increases vasocontraction, whereas the binding of ET-1 to ET B leads to vasorelaxation via the release of NO. [19] [20] [21] In the CC, ET A expression is dominant over ET B , and therefore, ET-1 mainly induces CSM contraction. 22, 23 Similar to NE, ET-1-induced CSM contraction is mediated by an increase in both [Ca 2 þ ] i 13, 24 and Ca 2 þ sensitization. 4 Evidence indicates that changes in the ET-1 pathway are involved in the pathophysiology of ED. Chang et al. 4 found that the expression of ET A receptors was significantly upregulated in the CSM of diabetic rabbits. Sullivan et al. 25 reported a significant decrease in ET B receptor binding sites in cavernosal tissue from hypercholesterolemic rabbits, and a significant increase in ET B receptor binding sites in cavernous tissue of diabetic rabbits. 26 5-HT. 5-HT is a monoamine neurotransmitter that has a variety of functions in the central nervous system as well as peripheral tissues. In the CC, 5-HT released from the serotonergic nerve fibers has a physiological role in the maintenance of penile flaccidity and the initiation of detumescence. 14, 27 Several studies showed that 5-HT induced contraction of isolated penile tissue, which could be blocked by 5-HT receptor antagonists. 14, [27] [28] [29] Further, pre-incubation with ROCK inhibitor Y-27632 attenuated maximum contraction induced by 5-HT of penile tissue, indicating that RhoA/ ROCK pathway is a mediator of 5-HT-induced contraction.
14 Evidence from human pulmonary arteries showed that Ca 2 þ influx and release from the intracellular Ca 2 þ store may also be involved in 5-HT-induced contraction. 15 Ang-II. Being an important component of the renin-Ang system, Ang-II is converted from Ang-I by Ang-converting enzyme (ACE) predominately in the lung. Ang-II binds to Ang receptors on the membranes of smooth muscle cells and other cell types, causing contraction via both Ca 2 þ -dependent 30 and Ca 2 þ -sensitizing 31 mechanisms, similar to the other agonists. Becker et al. 32, 33 reported that Ang-II levels were 30% higher in the cavernous blood than that in the systemic blood, indicating that Ang-II is produced locally in the CC. This is further supported by the findings that ACE is expressed in the endothelial cells of canine CC. 34 The dynamic changes in Ang-II levels in the cavernous blood during different penile states 32, 33 suggest that Ang II plays a physiological role in regulating penile tone. In organ-bath studies, Ang-II evoked dosedependent contraction of human 33 and rabbit 35 40, 41 The binding of agonists (NE and others) to their receptors on the cell membranes activates phospholipase C, which leads to the production of IP 3 58 The activity of the sarco(endo)-plasmic reticulum Ca 2 þ -ATPases in the CC is significantly higher than that in the bladder and urethra, and can be significantly downregulated by castration. 59 The role of the Na þ -Ca 2 þ exchangers and the plasma membrane Ca 2 þ -ATPases in the CSM is unclear.
MLCK and MLC: [Ca 2 þ ] i binds to calmodulin, and in turn, the Ca 2 þ /calmodulin complex activates MLCK. MLCK then phosphorylates the regulatory unit of MLC, allowing it to activate myosin ATPase. Activity of myosin ATPase permits ratcheting of myosin and actin myofilaments and muscular contraction. On the contrary, phosphorylated MLC can be dephosphorylated by MLC phosphatase, resulting in a reversal of contraction. 60, 61 At basal levels of tone, only B10% of the MLC in the CC exists in a phosphorylated state, a significantly lower level than that in the bladder (25%). Upon maximal stimulation by phenylephrine, the MLC in the CC reaches a phosphorylation level of 23%. 60 It has been shown that agonists (NE, ET-1, and so on) also augment G-protein-dependent downregulation of MLC phosphatase activity, resulting in an increase in the level of MLC phosphorylation, 62 which can be reversed by activating the NO-cGMP pathway. 63, 64 The Ca 2 þ -dependent pathways regulating smooth muscle contraction are summarized in Figure 1 .
RhoA/Rho-kinase: RhoA is a low-molecular-weight G protein, which is active in the GTP-bound state. The activation of RhoA requires both its translocation to cellular membrane and the post-translational addition of a geranylgeranyl phosphate onto it. [65] [66] [67] RhoA has numerous downstream targets, a predominant one of which is the ser/thr kinase, ROCK. ROCK has been shown to induce calcium sensitization of smooth muscle by phosphorylating the myosin binding subunit of MLC phosphatase, leading to the inhibition of MLC phosphatase activity. 68, 69 Some studies also suggest that ROCK may phosphorylate MLC directly. 70 ROCK-mediated inhibition of MLC phosphatase leads to the maintenance of the phosphorylated state of MLC, promoting vascular smooth muscle contraction. Numerous studies have demonstrated that the inhibition of RhoA/ROCK-mediated Ca 2 þ sensitization induces the relaxation of smooth muscle. [71] [72] [73] In a recent study, Li et al. 74 found that the penile RhoA/ROCK pathway was upregulated in diabetic rats, and chronic treatment with the ROCK inhibitor fasudil could restore erectile function by normalizing the Akt-driven pathway, indicating that the RhoA/ ROCK pathway plays a pivotal role in the pathogenesis of diabetic ED.
There are two isoforms of ROCK: ROCK1 (ROKb) and ROCK2 (ROKa). In humans, ROCK1 and ROCK2 genes are located separately on chromosomes 18 and 2, respectively. 75, 76 ROCK1 is preferentially expressed in inflammatory cells, whereas ROCK2 is highly expressed in vascular smooth muscle cells. 77 Wang et al. 78 reported that whereas a balance of ROCK1 and ROCK2 activities is required to Inhibition of smooth muscle tone as a treatment for ED X Jiang and K Chitaley regulate vascular smooth muscle actin cytoskeletal structure, ROCK2 is the predominant isoform that regulates vascular smooth muscle cell contractility. Both ROCK1 and ROCK2 are expressed in human and animal CC. 79, 80 Elevated expression of the ROCK2 protein was found in the cavernous tissue of spontaneous hypertensive rats 81 and rats that had undergone cavernous nerve injury, 82 in line with the findings that ROCK2 plays the major role in regulating vascular smooth muscle cell contractility. However, several studies indicate that the expression of ROCK1, rather than ROCK2, was significantly increased in penile tissues from different diabetic animal models. 4, 83, 84 In rabbits with bladder outlet obstruction, Chang et al. 80 found that the expression of both isoforms of ROCK in the CC is increased. The etiology-dependent changes in the expression of ROCK1 and ROCK2 indicate that they might play different roles in the pathophysiology of ED, which may have implications in the development of therapeutic options.
Telokin: Telokin, also known as kinase-related protein, is a 17-kDa smooth muscle-specific protein whose sequence is identical to the C-terminal domain of MLCK. 85, 86 It has been shown that telokin decreases smooth muscle contractility by inhibiting the phosphorylation of the regulatory unit of MLC by the MLCK. [87] [88] [89] [90] Increasing evidence shows that telokin also activates MLC phosphatase, and therefore, leads to Ca 2 þ desensitization. 85, [91] [92] [93] [94] Telokin knockout mice exhibit decreased MLC phosphatase activity, resulting in increased Ca 2 þ sensitivity in intestinal smooth muscle. 94 The activity and function of telokin in the cavernous tissue remains unclear.
PKC: PKC is a family of enzymes that are involved in controlling the function of other proteins through the phosphorylation of hydroxyl groups of serine and threonine amino-acid residues on these proteins. Activated by signals such as diacylglycerol or Ca 2 þ , PKC regulates smooth muscle tone via complex and diverse signal-transduction cascades. First, PKC regulates the activity of L-type VGCCs, non-selective cation transient receptor potential channels, Ca 2 þ -activated K þ channels and ATPsensitive K þ channels by phosphorylating them. 95 The function of PKC could be either activating or inhibiting these ion channels, depending on the cell type, the PKC isoforms involved and the concentration of PKC agonist. [95] [96] [97] Another mechanism by which PKC regulates smooth muscle tone is to increase Ca 2 þ sensitization via phosphorylation of CPI-17 (discussed next). In addition, PKC was found to inhibit NO synthase activity.
98-100 Increased PKC activity in diabetic human cavernous tissue has been reported, 101 indicating that the alteration of PKC activity might be involved in the pathogenesis of ED. However, Jin et al. 102 failed to detect any significant effect of a PKC activator or PKC inhibitors on the tone of mouse cavernous tissue, although there were significant effects on mouse aorta. CPI-17: CPI-17, known as PKC potentiated inhibitory protein of protein phosphatase-1, is a 17-kDa protein that can be phosphorylated primarily by PKC, although other kinases, such as ROCK and p21-activated protein kinase, have been suggested to phosphorylate CPI-17 as well. [103] [104] [105] [106] Phosphorylation at Thr-38 greatly increases the inhibitory potency of CPI-17, which in turn inhibits MLC phosphatase activity, 107 leading to increased phosphorylation of MLC and contraction of smooth muscle. 108 The phosphorylation of CPI-17 was diminished in decompensated bladder tissue, indicating that the activity level of CPI-17 is correlated with smooth muscle contractility. 109 CPI-17 expression was detected in human and rabbit CC; 79 however, its role in penile erection remains to be determined. Figure 2 illustrates the Ca 2 þ -sensitizing pathways regulating smooth muscle contraction.
Contractile signaling and ED
Diabetic ED Several lines of evidence showed that diabetic ED is associated with an imbalance towards enhanced penile vasoconstriction, resulting from changes in contractile signaling of the CSM at multiple levels. The concentration of penile NE was found to be increased in diabetic rats, 110 and elevated plasma level of ET-1 has been shown in diabetic patients. 111, 112 Chang et al. 5 found that the expression of ET A receptors was significantly upregulated Figure 2 Ca 2 þ -sensitizing pathways in smooth muscle cells. The binding of agonists (NE, ET, and so on) to their receptors on the cell membrane induces activation of RhoA. RhoA-GTP in turn activates ROCK, leading to the inhibition of MLC phosphatase activity by phosphorylation of the myosin binding subunit of MLC phosphatase. Furthermore, both PKC and ROCK can phosphorylate and activate CPI-17, which also inhibits MLC phosphatase activity, to promote smooth muscle contraction. Abbreviations: ET, endothelin; DAG, diacylglycerol; IP 3 , inositol trisphosphate; MLC, myosin light chain; MLCP, myosin lightchain phosphatase; MLCK, myosin light-chain kinase; NE, norepinephrine; P, phosphate; PLC, phospholipase C; PKC, protein kinase C; R, receptors; ROCK, Rho-kinase.
Inhibition of smooth muscle tone as a treatment for ED X Jiang and K Chitaley in the CC of diabetic rabbits and rats. 84 Sullivan et al. 26 reported a significant increase in ET B receptor binding sites in cavernous tissue of diabetic rabbits. As the downstream signaling of both NE and ET, RhoA/ROCK axis was found to be upregulated in diabetic animals as well. The expression of ROCK1, but not ROCK2, was significantly increased in penile tissues from different diabetic animal models, 4, 83, 84 indicating that ROCK1 is involved in diabetic ED. Furthermore, Angulo et al. 101 demonstrated that diabetes causes hypercontractility of human cavernous tissue by a mechanism involving overactivity of PKC.
Hypertension-related ED Similar to diabetic ED, hypertension-related ED may be related to augmented contractile signaling in the CC as well. Deoxycorticosterone acetate-salt-induced hypertensive animals showed increased cavernous contractile responses to both ET-1 and the a-adrenergic receptor agonist phenylephrine. 113, 114 As to the downstream signaling, although protein expression levels of ROCK in the CC of deoxycorticosterone acetate-treated animals were similar to those of control animals, the phosphorylated form of myosin phosphatase regulatory subunit, a downstream effector of ROCK, was increased in cavernous tissue from deoxycorticosterone acetate animals. 114 In the spontaneously hypertensive rat, Wilkes et al. 115 found that hypertension-related ED is associated with elevated penile RhoA levels and that inhibition of ROCK activity with Y-27632 was beneficial in attenuating the decline in erectile function. In another study, ROCK2 protein was found to be elevated in spontaneous hypertensive rats. 81 However, Behr-Roussel et al. 116 found both a reduced cavernous contractile response to phenylepherine and an impaired endothelium-dependent relaxation to acetylcholine in spontaneous hypertensive rats. The authors proposed that the pathophysiology of ED in hypertension is the result of an increase in cyclooxygenase-dependent constrictor tone, although a defect of endothelial or neuronal NO production and/or bioavailability cannot be excluded.
Aging-related ED
Aging is closely related to ED, and interestingly, despite an increased contractile response in the CC, 117 aged animals showed decreased (rather than increased) penile concentration of NE 110 and expression of L-type VGCC and ryanodine receptors. 118 It is possible that aging mainly impairs the relaxation signaling, resulting in 'unmasking' of the contractile signaling. However, Jin et al. 119 reported that though the expression of total RhoA remains unchanged, membrane-bound RhoA and phosphorylated myosin phosphatase regulatory subunit in the CC of aged rats are increased, indicating that enhanced RhoA and ROCK activity may play a role. Treatment with an Ang-II receptor antagonist 120 and the ROCK inhibitor Y-27632 121 also improve erectile function in aged animals, indicating that elevated contractile tone may be involved in aging-related ED.
ED caused by cavernous nerve injury
Cavernous nerve injury is another common cause of ED. Following cavernous nerve injury, animals show penile fibrosis, that is, decreased smooth muscle and increased collagen content. 122 Gratzke et al.
82
reported that bilateral cavernous nerve injury causes increased RhoA and ROCK2 protein expression, and increased RhoA GTPase and ROCK activity in rat CC. The penile ROCK1 protein expression is unchanged in these animals. However, Cho et al.
123
found increased ROCK1 expression in the CC of rats following cavernous nerve injury. In accordance with these findings, ICI of Y-27632 causes a significantly greater increase in intracavernosal pressure in nerve-injured rats compared to that in sham-operated rats. 123 
Inhibition of vasoconstriction to induce erection

Endogenous mechanisms
The main driving force for penile erection is NO-mediated signaling. Sexual stimulation or nocturnal tumescence activates neuronal NO synthase-mediated NO release from non-adrenergic non-cholinergic nerve endings 8, 124 initiating vasodilation. Subsequently, maintenance of dilation has been proposed to occur through sheer flowinduced endothelial NOS activation. 125 In the smooth muscle cell, NO stimulates soluble guanylate cyclase, activating cGMP-dependent protein kinase for cavernosal relaxation. 126 NO signaling was originally thought to induce vasodilation by modulation of [Ca 2 þ ] i , through events including the inhibition of L-type VGCCs, the activation of Ca 2 þ -dependent K þ channels, the promotion of plasma membrane Ca 2 þ -ATPases and Na þ -Ca 2 þ exchangers activity and the activation of sarco(endo)plasmic reticulum Ca 2 þ -ATP ases. 56, 127, 128 It is now clear that NO signaling can also inhibit Ca 2 þ -sensitizing mechanisms directly resulting in vasorelaxation. cGMP-dependent protein kinase can decrease levels of phosphorylated MLC through telokin-mediated activation of MLC phosphatase, 93 as well as direct inhibition of RhoA through its phosphorylation. 129, 130 Recombinant cGMP-dependent protein kinase has been shown to phosphorylate RhoA, destabilizing its membrane Inhibition of smooth muscle tone as a treatment for ED X Jiang and K Chitaley binding resulting in NO-mediated inhibit of RhoA/ ROCK activity. 129, 130 It is tempting to speculate that decreased NO bioavailability leads to an increase in RhoA/ROCK constrictor activity. Elevated ROCK activity may then mediate the increased vasoconstrictor sensitivity seen in various animal models of ED. Endogenously, decreased [Ca 2 þ ] i induced by NO may also lead to vasodilation through inactivation of PKC, rapid CPI-17 dephosphorylation as well as MLCK inactivation, resulting in rapid MLC dephosphorylation and relaxation. 131 Pharmacological therapies Blockage of upstream signaling (NE, ET-1, ANG-II). NE: The non-selective a-adrenoceptor blocker, phentolamine, can block the effect of NE by competitively binding to the a1-adrenoceptor in the CC, leading to the relaxation of the CSM. 132 In addition to the blockage of a-adrenoceptors, phentolamine may also induce relaxation of cavernous tissue by blocking ET-1 signaling. 133 However, ICI with 5 mg phentolamine only resulted in penile tumescence, but not rigidity in humans. 5 Currently, phentolamine is administered in conjunction with other vasoactive agents, such as papaverine, prostaglandin E1 and vasoactive intestinal polypeptide 5 as ICI therapies, with the advantages of lowering the dosages and therefore the adverse effects of the other agents. 134 The safety and efficacy of oral phentolamine in the treatment of ED have been explored. 135, 136 Compared to sildenafil, oral phentolamine has a higher incidence of adverse effects and is less effective in improving penile erection. 136 Selective a1-adrenoceptor antagonists are commonly used to treat lower urinary tract symptoms. Studies showed that they slightly improved erectile function as well. 137, 138 An additive effect was observed when the selective a1-adrenoceptor antagonist alfuzosin was used together with sildenafil to treat ED. 139 ET-1: An ET A receptor antagonist was shown to increase the duration of nerve-stimulated elevations in intracavernosal pressure in rabbits, although the peak pressure values were not altered. 6 Despite the efficacy of the ET A receptor antagonist in animal studies, oral administration of this drug to men with mild-to-moderate ED did not significantly improve erectile function compared to placebo. 6 This disparity in efficacy between lab studies in rabbits and clinical studies was possibly due to important differences between species with regard to the role of ET-1 in erectile function. This is further supported by the findings in rats that ET receptor antagonists do not significantly alter the erectile response, although they inhibit potent contractions to exogenous ET-1. 140 Nevertheless, treatment with ET receptor antagonists for 2 weeks reversed cavernous apoptosis in diabetic rats, 141 indicating that chronic administration of ET receptor antagonists might be beneficial in the protection of erectile tissue. Ang-II: ACE inhibitors and Ang-II receptor blockers are widely used antihypertensive drugs. Since blockage of the Ang-II pathway results in smooth muscle relaxation, these agents might be beneficial in the treatment of ED. Animal studies showed that Ang-II receptor antagonists improved penile function in aged animals or animals with dyslipidemia. 120, 142 Another study showed that the ACE inhibitor captopril corrected both the blood pressure and erectile response of hypertensive rats to control levels. 143 Several small clinical studies have also suggested that treatment with Ang-II receptor blockers or ACE inhibitors are associated with improved erectile function and sexual performance in patients with hypertension and diabetes mellitus. [144] [145] [146] However, a recent double-blind, randomized study, involving 1549 patients, failed to reveal any significant effect of an Ang-II receptor blockers or an ACE inhibitor on ED. 148, 149 CSM contracted by a-adrenergic agonists in vitro. However, ICI of CCBs in dogs was less effective and had more side effects compared to papaverine. 150 The results of clinical trials with oral CCBs in the treatment of ED are disappointing. CCBs exert either no effect or a negative effect on erectile function. 151, 152 The safety and efficacy of ICI of CCBs have also been studied. 153, 154 Although the side effect of ICI of CCBs was comparable to other agents, CCBs may not be as effective as blockade of a-adrenoceptors. 148, 153, 154 Blockage of Ca 2 þ -sensitizing pathway (mainly RhoA/ROCK). Ten years ago, the inhibition of ROCK by ICI of Y-27632 was found to induce an erectile response in rats. 7 This effect did not require activation of NO-mediated signaling, thus introducing a potential target pathway for the treatment of ED, with potential extended benefit in cases where NO bioavailability was attenuated and thus phosphodiesterase type 5 (PDE5) inhibitors were less efficacious. At this point, ROCK inhibitors are being developed and tested for a wide range of potential uses. In Japan, the ROCK inhibitor fasudil has been used to treat vasospasm following subarachnoid hemorrhage 155 and pulmonary hypertension. 156 One animal study showed that chronic administration of oral fasudil prevented the development of ED and pelvic atherosclerosis. 157 Another study using
Inhibition of smooth muscle tone as a treatment for ED X Jiang and K Chitaley diabetic rat models demonstrated that fasudil restores erectile function by suppressing corporal apoptosis caused by diabetes. 74 These promising results from animal studies indicate the possibilities of administration of ROCK inhibitors either acutely to induce erection or chronically to prevent or reverse ED. To date, the effect of ROCK inhibitors in the treatment of ED in humans has not been reported. In the era of oral therapy for ED, ICI therapy becomes less attractive. However, one potential problem with systemic administration of ROCK inhibitors is whether it would cause profound extra-cavernosous effects, such as hypotension. Further, the two ROCK isoforms share B90% homology in their kinase domains. 158 This has made it quite challenging to develop isoform-selective inhibitors for clinical use. A recent compound, SLx2119 (Surface Logix), is unique in its specificity for only ROCK2. 159 A summary of the outcomes of both animal and human studies on the pharmacological targets modulating CSM contraction for the treatment of ED is shown in Table 1 . The most significant advances during the past decade are listed as follows: a-Adrenoceptor antagonists have an additive effect when administered together with other ED medications. Chronic administration of ET receptor antagonists is beneficial in the protection of erectile tissue in rats. However, data in humans are lacking. Chronic administration of ROCK inhibitors prevents ED or restores erectile function in animals. However, clinical studies are needed.
Conclusions
This review outlines contractile signaling pathways, which play a role in the maintenance of penile flaccidity. The potential for therapeutic intervention at the level of smooth muscle contraction, bypassing the need for intact NO-dependent signaling, is especially appealing for the treatment of ED associated with co-morbidities such as diabetes or prostatectomy, where NO signaling may be impaired. However, more than 10 years after the discovery of potent contractile signaling pathways in the cavernosum, we remain far from such targeted therapeutics. The most promise for therapeutic intervention has been found with the inhibitor of ROCK signaling. The availability of the ROCK inhibitor fasudil in Japan for the treatment of other conditions makes clinical studies of its efficacy and safety in the treatment of ED possible. Furthermore, isoform-selective ROCK inhibitors may be indicated in the treatment of ED with different etiologies with a reduced systemic side effect, although various obstacles, such as isoform homology and lack of tissue specificity, have hindered their development. Other potential targets in both Ca 2 þ -dependent and Ca 2 þ -sensitizing signaling pathways may be explored for benefits in the treatment of ED. Combined blockages of multiple targets in these pathways may enhance the efficacy in promoting penile erection. Development of these targeted therapeutics, which may benefit even cohorts refractory to PDE5 inhibition, are certainly promising and warranted. 
